
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst is facing challenges with its ongoing transition from its DOS platform to Ignite, leading to potential customer attrition and down-selling. Despite this, there are positive signs with the company signing 32 new platform customers in 2025, exceeding its revised target and indicating traction with the new platform. The revenue impact in FY26 and FY27 related to this transition is being better defined, with an expected retention of at least $22M of the $52M ARR pool and an estimated $30M churn or down-sell, resulting in a back half stepdown in revenue.
Bears say
Health Catalyst is facing headwinds in the form of booking delays for its data platform and analytics applications due to migration-related challenges and reduced retention of ARR related to DOS decisions. This has led to a forecast for a decline in revenue and adjusted EBITDA for fiscal year 2026, as well as a lowered price target. While there is potential for value in the company's assets and potential deals in the market, the negative outlook is based on the current challenges and uncertain future performance.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares